Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Matthias Mann; Laura Lauman; and More

Premium

The German Research Foundation this week named Matthias Mann one of eleven winners of the 2012 Leibniz Prize for his work in the development of mass spec-based proteomics.

A director at the Max Planck Institute of Biochemistry in Martinsried, Mann is the developer of a number of widely used proteomics techniques and platforms, including the SILAC protein labeling method and the MaxQuant bioinformatics software. One of the Germany’s most prestigious scientific awards, the Leibniz Prize comes with €2.5 million ($3.3 million) in cash. The awards ceremony will be held on Feb. 27, 2012, in Berlin.


Harvey Millar this week received the Australian Academy of Science’s 2012 Fenner Medal in recognition of his work in plant proteomics.

Millar is a chief investigator at the ARC Centre of Excellence in Plant Energy Biology at the University of Western Australia and the director of the UWA Center for Comparative Analysis of Biomolecular Networks. His research focuses on plant respiration, energy production, and response to environmental stress.

The Fenner Medal is given each year to a scientist under 40.


Illumina announced this week that it has appointed Laura Lauman vice president of marketing.

Previously, Lauman was president of AB Sciex. Before that she was general manager of Life Technologies/Applied Biosystems’ Proteomics and Small Molecule division.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more